CytoMed Therapeutics Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
The notice leaves current listing, trading and business operations unaffected, while compliance must be restored within the grace period.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CytoMed Therapeutics (NASDAQ: GDTC) received a Nasdaq notice on October 6, 2026, identifying a minimum bid price deficiency for its ordinary shares. The closing bid price had been below US$1.00 for 30 consecutive business days. The notice has no current effect on listing or trading and does not affect business operations.
The company has until April 5, 2027 to regain compliance by maintaining a closing bid price of at least US$1.00 for at least ten consecutive business days. An additional 180-day period may be available, subject to Nasdaq's determination and other listing standards. That extension requires written intent to cure the deficiency, through a reverse stock split if necessary.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Minor pointCurrent listing, trading and business operations are unaffected by the Nasdaq notification.
Negative
- Moderate pointMinimum bid price deficiency follows 30 consecutive business days with closing bids below US$1.00.
- Minor point. Forward-looking: it has not happened yet and may not happen.April 5, 2027 deadline requires at least ten consecutive business days of closing bids at US$1.00 or higher.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional 180-day period depends on Nasdaq's determination, other listing standards and written intent to cure, including a reverse split if necessary.
Key Figures
- Minimum bid price
- $1.00 per share
- Nasdaq minimum closing bid price requirement
- Deficiency period
- 30 consecutive business days
- Closing bid price was below the minimum requirement
- Initial compliance period
- 180 calendar days, through April 5, 2027
- Period to regain Nasdaq bid-price compliance
- Compliance price condition
- At least 10 consecutive business days at $1.00 per share or higher
- Condition for regaining compliance during the initial period
- Potential additional compliance period
- 180 days
- May be available if the company meets specified continued-listing and initial-listing standards
Key Terms
allogeneic immunotherapies medical
reverse stock split financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SINGAPORE, Oct. 09, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (the “Company”) (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies, today announced that on October 6, 2026, the Company received a notice from the staff of the Nasdaq Listing Qualifications department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company’s ordinary shares (the “Ordinary Shares”) was below the minimum bid price of US
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until April 5, 2027, to regain compliance under the Nasdaq Listing Rules. If at any time during the 180-day compliance period, the closing bid price of the Company’s Ordinary Shares is US
The Nasdaq notification letter does not affect the Company’s business operations, and the Company intends to take all reasonable measures to regain compliance within the prescribed grace period.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company’s current and future pre-clinical studies and clinical trials and the Company’s R&D programs; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company’s ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention : Evelyn Tan, Chief Corporate Officer
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.